Resource Summary Report

Generated by RRID on Sep 9, 2026

MFE-296

RRID:CVCL_1406
Type: Cell Line

Proper Citation

RRID:CVCL_1406

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1406

Proper Citation: RRID:CVCL_1406

Description: Cell line MFE-296 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Endometrial adenocarcinoma

Defining Citation: PMID:8150529, PMID:9620227, PMID:20164919, PMID:22460905, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MFE-296

Synonyms: MFE 296, MFE296

Cross References: CLO:CLO_0007693, CLDB:cl5081, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:942, BioSample:SAMN03473590, BioSample:SAMN10987797, cancercelllines:CVCL_1406, Cell_Model_Passport:SIDM00334, ChEMBL-Cells:CHEMBL3308374, ChEMBL-Targets:CHEMBL1075503, Cosmic:908130, Cosmic:1105621, Cosmic:1177684, Cosmic:1434195, Cosmic:1576463, Cosmic:2030479, Cosmic-CLP:908130, DepMap:ACH-000879, DSMZ:ACC-419, DSMZCellDive:ACC-419,

ECACC:98031101, EGA:EGAS00001000978, GDSC:908130, GEO:GSM374975, GEO:GSM375434, GEO:GSM844604, GEO:GSM844605, GEO:GSM887312, GEO:GSM888388, GEO:GSM1670099, IARC_TP53:21496, LiGeA:CCLE_405, LINCS_LDP:LCL-1501, PharmacoDB:MFE296_920_2019, PRIDE:PXD030304, Progenetix:CVCL_1406, PubChem_Cell_line:CVCL_1406, Wikidata:Q54905382

ID: CVCL_1406

Record Creation Time: 20220427T220804+0000

Record Last Update: 20260905T181139+0000

Ratings and Alerts

No rating or validation information has been found for MFE-296.

No alerts have been found for MFE-296.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Pham BQ, et al. (2025) mTORC1 regulates the pyrimidine salvage pathway by controlling UCK2 turnover via the CTLH-WDR26 E3 ligase. Cell reports, 44(1), 115179.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. Molecular systems biology, 21(8), 983.

Yi SA, et al. (2024) mTORC1-CTLH E3 ligase regulates the degradation of HMG-CoA synthase 1 through the Pro/N-degron pathway. Molecular cell, 84(11), 2166.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer discovery, 13(9), 2012.

Zhang W, et al. (2023) HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation. Cell reports, 42(11), 113352.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Molecular cell, 81(4), 708.